Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (12)

2016

  1. Potential risk for inappropriate dyslipidemia screening in Primary Care in Spain

    Revista del Laboratorio Clinico, Vol. 9, Núm. 2, pp. 48-53

  2. Request of thyroid function tests from Primary Care in Spain

    Endocrinologia y Nutricion, Vol. 63, Núm. 1, pp. 19-26

2015

  1. Potential over request in anemia laboratory tests in primary care in Spain

    Hematology, Vol. 20, Núm. 6, pp. 368-373

2014

  1. A study of the differences in the request of glycated hemoglobin in primary care in Spain: A global, significant, and potentially dangerous under-request

    Clinical Biochemistry, Vol. 47, Núm. 12, pp. 1104-1107

  2. Variation in laboratory tests ordered for patients treated in hospital emergency departments

    Emergencias, Vol. 26, Núm. 6, pp. 450-458

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229

2005

  1. Effectiveness of different methods for anti-Sm antibody identification. A multicentre study

    Clinical Chemistry and Laboratory Medicine, Vol. 43, Núm. 7, pp. 748-752

  2. Sensibilidad in vitro a los antibióticos y serotipos más frecuentes de Streptococcus pneumoniae. Estudio multicéntrico

    Revista Espanola de Quimioterapia, Vol. 18, Núm. 1, pp. 45-51

2003

  1. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum

    International Journal of Antimicrobial Agents, Vol. 22, Núm. 5, pp. 492-496

  2. Situación actual de las pruebas de autoanticuerpos en los laboratorios españoles de análisis clínicos y bioquímica clínica

    Quimica Clinica, Vol. 22, Núm. 6, pp. 409-418

2002

  1. In vitro activity of linezolid, synercid and telithromcin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 1, pp. 61-64